Global MRSA Drugs Market 2016-2020

  • ID: 3802192
  • Report
  • Region: Global
  • 79 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Absynth Biologics
  • Basilea Pharmaceutica
  • CrystalGenomics
  • KYORIN Pharmaceutical
  • Nabriva Therapeutics
  • R-Pharm
  • MORE
About Methicillin-Resistant Staphylococcus aureus (MRSA)

MRSA is an infection of the skin that occurs mostly in hospitals and healthcare facilities. It is treated with commonly-used antibiotics and usually spreads from person to person by direct skin-to-skin contact. Physicians often find MRSA harder to treat than most other strains of Staphylococcus aureus because it is sometimes resistant to commonly-used antibiotics such as methicillin.

The analysts forecast the global MRSA drugs market to grow at a CAGR of 1.34% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global MRSA drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent MRSA infections.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global MRSA Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Allergan
- Merck & Co.
- Pfizer
- Theravance Biopharma

Other prominent vendors
- Absynth Biologics
- AmpliPhi Biosciences Corporation
- AstraZeneca
- Basilea Pharmaceutica
- Baxter International
- Cellceutix
- Cempra Inc.
- CrystalGenomics
- Debiopharm Group
- Galapagos NV
- GSK
- KYORIN Pharmaceutical
- Lytix Biopharma
- Melinta Therapeutics
- Nabriva Therapeutics
- NovaDigm Therapeutics
- Paratek Pharmaceuticals
- R-Pharm
- Savara Pharmaceuticals
- Sealife Pharma
- Sequella Inc.
- The Medicines Company
- XBiotech

Market drivers
- Special regulatory designations
- For a full, detailed list, view the full report

Market challenges
- Development of drug-resistant strains
- For a full, detailed list, view the full report

Market trends
- Strategic alliances and M&A
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Absynth Biologics
  • Basilea Pharmaceutica
  • CrystalGenomics
  • KYORIN Pharmaceutical
  • Nabriva Therapeutics
  • R-Pharm
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Key buying criteria

PART 06: Antibacterial: Overview
  • Introduction
  • MOA
  • General principles for use of antibiotics
  • Clinical uses
PART 07: Antimicrobial resistance
  • Sources of spread of resistant organisms
  • Initiatives to improve antibiotic innovation
  • Surveillance systems for antibiotic resistance
PART 08: Legislation relating to antibiotics use in US

PART 09: Pipeline analysis
  • Solithromycin
  • TD-1792
  • Baxdela
  • Taksta
PART 10: Market landscape
  • Global antibacterial drugs market
  • Global MRSA drugs market
  • Five forces analysis
PART 11: Market segmentation by drug class
  • Tetracycline
  • Folate antagonists
  • Cephalosporin
  • Lipopeptide
  • Oxazolidinone
  • Lipoglycopeptide
PART 12: Market segmentation by drug origin
  • Semisynthetic drugs
  • Synthetic drugs
PART 13: Market segmentation by MOA
  • Bacteriostatic
  • Bactericidal
PART 14: Geographical segmentation
  • Global MRSA drugs market by geographical segmentation 2015-2020
  • MRSA drugs market in Americas
  • MRSA drugs market in EMEA
  • MRSA drugs market in APAC
PART 15: Market drivers
  • Special regulatory designations
  • Increasing prevalence of infections
  • Growing awareness of diseases
  • Rise in older population
PART 16: Impact of drivers

PART 17: Market challenges
  • Development of drug-resistant strains
  • Patent expiries and generic penetration
  • Decreased investments in research activities
PART 18: Impact of drivers and challenges

PART 19: Market trends
  • Strategic alliances and M&A
  • Patient assistance programs
  • Increased funding for antibiotic research
PART 20: Vendor landscape
  • Competitive scenario
  • Key vendor profiles
  • Allergan
  • Merck
  • Pfizer
  • Theravance
  • Other prominent vendors
PART 21: Appendix
  • List of abbreviations
PART 22: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Percentage of MRSA infections among Staphylococcus infections in US 2015
Exhibit 03: Percentage of MRSA infections in US based on type 2015
Exhibit 04: Sites of Staphylococcus infections
Exhibit 05: Key buying criteria for MRSA drugs
Exhibit 06: MOA of antibacterial drugs
Exhibit 07: General principles involved in use of antibiotics
Exhibit 08: Causes of AMR
Exhibit 09: Sources of spread of resistant organisms
Exhibit 10: Estimated deaths per year caused by AMR in 2050
Exhibit 11: Initiatives improving antibiotic innovation
Exhibit 12: Surveillance systems of various countries
Exhibit 13: Legislation relating to antibiotics use in US
Exhibit 14: Pipeline portfolio: Global MRSA drugs market
Exhibit 15: Global antibacterial drugs market 2015-2020 ($ billions)
Exhibit 16: Market share of global MRSA drugs in global pharmaceutical market 2015
Exhibit 17: Global MRSA drugs market 2015-2020 ($ billions)
Exhibit 18: Five forces analysis
Exhibit 19: Cephalosporin segmentation by generation of drugs
Exhibit 20: Global MRSA drugs market segmentation based on volume 2015
Exhibit 21: Global MRSA drugs market segmentation by drug origin
Exhibit 22: Global MRSA drugs market segmentation by geography 2015
Exhibit 23: Global MRSA drugs market revenue by geography 2015-2020 ($ millions)
Exhibit 24: Percentage share of global MRSA drugs market by geography 2015-2020
Exhibit 25: MRSA drugs market in Americas 2015-2020 ($ billions)
Exhibit 26: Percentage share of MRSA drugs market in US 2015
Exhibit 27: MRSA drugs market in EMEA 2015-2020 ($ millions)
Exhibit 28: MRSA drugs market in APAC 2015-2020 ($ millions)
Exhibit 29: Global MRSA drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 30: Percentage of MRSA infections 2014
Exhibit 31: Impact of drivers
Exhibit 32: Antibiotic-resistant strains of Staphylococcus according to period of development of resistance
Exhibit 33: Ranking for top ten countries based on antibiotic consumption in livestock 2015
Exhibit 34: Antibacterial drug approvals by FDA and EMA
Exhibit 35: Impact of drivers and challenges
Exhibit 36: Allergan: Key takeaways
Exhibit 37: Merck: YoY revenue and growth rate of Cubicin 2013-2015 ($ billion)
Exhibit 38: Merck: Key takeaways
Exhibit 39: Pfizer: YoY revenue and growth rate of Zyvox 2013-2015 ($ millions)
Exhibit 40: Pfizer: YoY revenue and growth rate of Tygacil 2013-2015 ($ millions)
Exhibit 41: Pfizer: Key takeaways
Exhibit 42: Theravance Biopharma: YoY revenue comparison of Vibativ 2014-2015 ($ millions)
Exhibit 43: Theravance: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Absynth Biologics
  • Basilea Pharmaceutica
  • CrystalGenomics
  • KYORIN Pharmaceutical
  • Nabriva Therapeutics
  • R-Pharm
  • MORE
New Report Released: – Global MRSA Drugs Market 2016-2020

The author of the report recognizes the following companies as the key players in the global MRSA drugs market: Allergan, Merck, Pfizer, and Theravance.

Other Prominent Vendors in the market are: Absynth Biologics, AmpliPhi Biosciences, AstraZeneca, Basilea Pharmaceutica , Baxter International, Cellceutix, Cempra, CrystalGenomics, Debiopharm, Galapagos NV, GSK, KYORIN Pharmaceutical, Lytix Biopharma, Melinta Therapeutics, Nabriva Therapeutics, NovaDigm Therapeutics, Paratek Pharmaceuticals, R-Pharm, Savara Pharmaceuticals, Sealife Pharma, Sequella, The Medicines Company, and XBiotech.

Commenting on the report, an analyst from the research team said: “Strategic alliances and M&A will be the key trend for market growth. Strategic alliances help co-develop and commercialize drugs. These agreements enable the use of technical expertise from both companies, as well as the use of regulatory and development experience gained by one company for the support of pipeline candidates of another company. They ensure the in-flow of adequate funds from both the companies, reducing liability costs for individual companies in case of failures. M&A are usually intended to increase the market penetration of the acquirer or enhance the product portfolio of the parent company.”

According to the report, growing awareness of diseases will be a key driver for market growth because it has increased the use of drugs. October is celebrated as World MRSA Awareness Month. European Antibiotic Awareness Day was celebrated on November 18, 2014 to raise awareness of antibiotic resistance and promote judicious use of antibiotics. The US Department of Health and Human Services developed Healthy People 2020, which aims to prevent and treat infectious diseases. Other awareness programs include World Hand Hygiene Day on May 5, National Infection Control Week in the third week of October, World Pneumonia Day on November 12, and Antibiotic Awareness Week in the third week in November. These programs help increase the treatment seeking population, thus driving the market.

Further, the report states that patent expiries and generic penetration will be the challenges for by the market. The loss of patent exclusivity of branded drugs results in the development of generic formulations, which are similar in quality, dosage form, strength, and efficacy, but less costly. There has been a significant increase in generic competition because of the patent expiries of major MRSA drugs. In the emerging markets of Asia, Africa, and South America, the increase in generic competition is leading to downward pricing pressures, which challenges market expansion.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- Allergan
- Merck
- Pfizer
- Theravance
- Absynth Biologics
- AmpliPhi Biosciences
- AstraZeneca
- Basilea Pharmaceutica
- Baxter International
- Cellceutix
- Cempra
- CrystalGenomics
- Debiopharm
- Galapagos NV
- GSK
- KYORIN Pharmaceutical
- Lytix Biopharma
- Melinta Therapeutics
- Nabriva Therapeutics
- NovaDigm Therapeutics
- Paratek Pharmaceuticals
- R-Pharm
- Savara Pharmaceuticals
- Sealife Pharma
- Sequella
- The Medicines Company
- XBiotech
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll